Disseminated Mycobacterium avium complex (MAC) infection has reached epidemic proportions and is a major cause of morbidity and mortality in AIDS patients. We have developed a liposomal preparation of amikacin, VS107, which incorporates the drug in 54-65 nm diameter unilameller phospholipid vesicles and is stable at 4°C for more than 4 months. VS107 exhibits superior microbiological and pharmacological activity over the free amikacin and improves the survival of mice in the established model for MAC infection. The serum half-life of VS107 in mice was 9.1 h and a peak serum level of 730 mg/L was obtained after administering three doses of 160 mg/kg. For the therapeutic study, beige mice infected with 10' cfu M. avium complex strain 101 were randomised to be treated with placebo liposomes, buffer, free amikacin or VS107 The drugs were administered via the caudal vein thrice weekly for 1, 3, 5 or 7 weeks beginning 5 days after infection. After 51 days of treatment with VS107, the number of viable M. avium in the liver and spleen was a 100 fold lower than was achieved with conventional amikacin (P < 0.01), and more than six decimal logarithms lower than was found untreated controls (P < 0.001). VS107 was well tolerated and might be a suitable candidate for treating human MAC infections.
Introduction
Infections caused by the Mycobacterium avium complex (MAC) have become one of the most common bacterial infections associated with the AIDS epidemic (Nightingale et al., 1992) . The treatment of MAC infection continues to present major challenge since not only is the bacterial burden high but the host is profoundly immunocompromised. The antibiotic compounds which show some activity both in vitro and in vivo include rifamycins, fluoroquinolones, ethambutol, clofazimine, macrolides and aminoglycosides (Heifets, Iseman & Lindholn-Levy, 1987; Inderlied, Young & Yamada, 1987; Young, 1988; Khardori et al., 1989; Heifets & Iseman, 1990; Heifets, 1991; Horsburgh, 1991; Young et al., 1991; Kemper et al., 1992; Kerlikowske et al., 1992; Rathbun et al., 1991; Benson & Ellner, 1993) . Combination therapy with two or more drugs is usually necessary to minimize the risk that drug resistance will develop as a result of the large bacterial burden. Amikacin has been included in some regimens (Chiu et al., 1990 ), but its efficacy may be limited by its rapid clearance from circulation, its inability to achieve high intracellular concentrations and its potential for toxic side effects. Liposomal encapsulation offers a method of overcoming these limitations and several studies have demonstrated that liposomal preparations of amikacin exhibit enhanced activity against experimentally induced MAC infection in beige mice (Gangadharam et al., 1983 (Gangadharam et al., , 1987 Bertram et al., 1986; Duzgunes et al., 1988; Chiasson & Hopewell, 1989; Cynamon et al., 1989; Inderlied et al., 1989; Bermudez et al., 1990) as well as against MAC infection in macrophages in vitro (Bermudez, Wu & Young, 1987; Inderlied et al., 1987; Kesavalu et al., 1990) . We have developed a new unilamellar liposomal formulation of amikacin, VS107 and now present its pharmacokinetics, toxicity, and activity against MAC infection in the beige mouse model compared to those of free amikacin.
Materials and methods

Preparation of inoculum
M. avium complex (strain 101, serotype 1) was kindly provided by Dr Lowell Young of the Kuzell Institute, San Francisco, CA, USA and was cultured at 37°C for 5 and 10 days respectively in Middlebrook 7H9 broth and 7hl 1 agar which were supplemented with oleate-albumin-dextrose-catalase (OADC) (Difco Laboratories, Detroit, MI, USA). An inoculum of 5 x 10 7 cfu/mL was prepared by suspending fresh culture in sufficient Middlebrook 7H9 to conform to the 0.5 McFarland standard. Each mouse was inoculated with 0.2 mL and the viable count was determined by plating decimal dilutions onto 7H11-OADC agar.
Beige mice
Four to six week-old Beige C57BL/6J-bg J /bg J mice weighing 20-25 g were obtained from Jackson Laboratories (Bar Harbor, ME, USA). All experimental procedures conformed to standards established by the Animal Welfare Act (Public Law 89-544, 1966 , as amended in 1985 and the Public Health Service Animal Care Guide as enforced by the University of Arizona Institutional Care and Use Committee.
Drugs
A stock solution of 259 mg/mL amikacin was prepared by dissolving the free base (Abbott Laboratories, North Chicago, IL, USA) in an aqueous solution of 10 mM sodium phosphate in 9% sucrose and titrating with dilute HO to pH 7.4. Liposomes without drug (Vestar, San Dimas, CA, USA) were prepared in a 2:1:0.1 molar ratio of hydrogenated soy phosphatidylcholine (Lipoid KG, Ludwigshafen, Germany), cholesterol (Sigma Chemical Co., St. Louis, MO, USA) and the sodium salt of distearoyl phosphatidylglycerol (Avanti Polar Lipids, Inc, Birmingham, AL, USA), and the entire lipid mixture dried from chloroform and methanol (2/1, v/v). After hydrating the lipid mixture at 65°C in either an aqueous solution of 10 mM sodium phosphate in 9% sucrose at pH 7.4 or 10 mM sodium succinate in 9% sucrose at pH 6.5, liposomes were formed by either sonication using a model VC500 with a 1/2" titanium probe (Sonics and Materials, Danbury, CT, USA ) for 20-30 min or by homogenisation with a commercial device (APV Gaulin, Everett, MA). Liposomal amikacin (VS107, Vestar Inc., San Dimas, CA, USA) was prepared by mixing the dried lipid mixture with amikacin stock solution, hydrating at 65 C C, and either sonicating or homogenising as before. Unencapsulated drug was removed by Sephadex G-50 filtration or by ultrafiltration with a Minitan apparatus (Millipore Corp., Bedford, MA, USA). The physical and chemical stability of VS107 was assessed using preparations that had been stored at 4°C for up to 4 months. Lipid and drug concentrations were assayed by HPLC analysis. The degree of amikacin encapsulation was based on the amount of drug recovered in the liposome fraction after Sephadex G-50 chromatography and expressed as a percentage. The size distribution of VS107 was determined using an ultrafine particle size analyzer (Microtrac, Petersburg, FL, USA).
Plasma stability of VS107
Equal volumes of VS107 and EDTA-treated rat plasma (Harlan Bioproducts for Science, Indianapolis, IN, USA) were mixed together and incubated at 37°C for up to 48 h. After the desired length of incubation, an aliquot of the mixture was centrifuged at 15,000 g for 5 min and 1 mL of the clear supernatant was loaded onto a 1.6 x 24 cm Sephacyl S-400 column (Pharmacia Biotech, Piscataway, NJ, USA) which had previously been equilibrated with the hydration buffer. The column was developed at a flow rate of 0.5 mL/min and an absorbance at 280 nm. The liposome fractions which eluted near the void volume and before the major portion of the plasma components were collected and allowed free amikacin to be completely separated from that associated with the liposome fractions. The concentration of amikacin in each fraction was assayed using the TD, fluorescence polarisation immunoassay (Abbott Laboratories, Abbott Park, Chicago, IL, USA) and the amount of cholesterol was determined by HPLC analysis using a C8 reversed phase column and a mobile phase of isopropanol: methanol: 0.5 M tetrabutylammonium phosphate: 1.0 M choline chloride in a molar ratio of 4:91:2.5:2.5. As a control, the concentrations of amikacin and cholesterol were determined in VS107 that had not been passed over the column. The relative ratio of these two components was arbitrarily set to 1. The recovery of liposomes from the column was determined by comparing the amount of cholesterol recovered in the liposome fraction with that found in the unchromatographed sample. The relative amount of encapsulated amikacin was determined from the ratio of amikacin to cholesterol in the liposome fractions to that in unchromatographed VS107.
Treatment
A group of six mice were used for each treatment regimen and each mouse was inoculated with 0.2 mL 1 x 10 7 cfu/mL MAC 101 via the caudal vein. Five days later, treatment was initiated. The dose of drug administered was based on a mean weight for mice of 22.5 g and mice were injected thrice weekly for periods of 1, 3, 5 and 7 weeks with 0.1-0.35 mL volumes of buffer, 120 mg/kg free amikacin, 40-120 mg/kg VS107 or empty liposomes at a concentration of lipid equivalent to that of highest dose of liposomal amikacin. Two days after discontinuing the treatment, the animals were killed by cervical dislocation and their livers and spleens were removed to allow the numbers of viable MAC 101 to be determined.
Determining the dose response of free amikacin and VS101
Groups of six mice were inoculated with 1 x 10 7 cfu/mL MAC 101 as before and treated with either 40-320 mg/kg VS107 or 40, 80, and 150 mg/kg free amikacin thrice weekly for 3 weeks. Two days after the end of treatment, the animals were killed and their livers and spleens were removed to allow the numbers of viable MAC 101 to be determined.
Enumeration of viable of organisms
Livers and spleens were weighed and homogenised in glass vessels. Decimal dilutions were prepared in a sterile aqueous solution, pH 5, and 50 /iL were plated in duplicate onto Middlebrook 7H11-OADC agar. The plates were incubated at 37°C for 10 days in 5% CO:. The number of cfu/g tissue was then determined.
Pharmacokinetics of VS107
VS107 was injected into adult male CD-I mice weighing 28-34 g (Jackson Laboratories, Bar Harbor, ME, USA) using a volume of 0.1 mL/lOg. Three consecutive doses of 160 mg/kg drug were given on alternate days. Three mice were selected at each of several time points up to 16 h after the third dose and were anaesthetized with ether before collecting 1 mL of blood by cardiac puncture. The blood was centrifuged to obtain 0.4 to 0.6 mL of serum which was then frozen at -20°C until required. The total concentration of both liposomal and free amikacin was determined by fluorescent polarisation immunoassay as before. The elimination constants for two apparent phases of elimination were determined from the plot of the concentration versus time.
Statistical analysis
The geometric mean of the cfu/g tissue of the livers and spleens of each treatment group was calculated and transformed to the decimal logarithm to permit treatment groups to be compared by an analysis of variance and the calculation of the parametric Duncan Multiple range test using the Statistical Package for the Social Sciences (STSS/TC + version 4.0) (SPSS, Chicago, IL, USA).
Results
Physical and chemical stability of VS107
During storage at 4°C for up to 4 months the mean liposome size changed by less than 5 nm, the pH was stable and no degradation of lipid was detected. After 4 months, over 90% of the initial amount of amikacin was detected, of which 93-98% remained associated with the liposome fraction.
Plasma stability of VSI07
With the exception of the initial sample of VS107 that was passed over the Sephacyl S-400 column, the total liposome recovery from the column was in the range of 80 to 100% (Table) . Immediately after mixing VS107 with the plasma, approximately 12% of the amikacin was removed from the liposome fraction and during the first hour of incubation, an additional 21% of the drug was released. Thereafter, there was no significant leakage of amikacin. Thus, approximately two-thirds of the encapsulated amikacin remained entrapped within liposomes under simulated physiological conditions.
Comparative activity of free amikacin to controls
In the longitudinal study, there was an increase in bacterial load in the spleen and liver of mice treated with buffer to approximately 10'cfu/g after 1 week's treatment, i.e. 14 days after infection, and approximately 10 10 cfu/g after 7 weeks treatment, i.e. 56 days after infection (Figure 1) , and the mortality was less than 10%. Treatment with liposomes alone did not affect the course of infection as only slight differences in viable counts were observed between animals treated with buffer and those given empty liposomes. The maximal effect of treatment with free amikacin was observed after 51 days treatment when a 4 log reduction in viable counts was found in the liver and a 3 log reduction in the spleen (P < 0.001).
Dose response of free amikacin
Treatment with 40 mg/kg free amikacin led to a reduction of approximately a 1 logio in the viable counts in both liver and spleen. Treatment with 80 mg/kg drug further reduced viable counts in the liver by 80% and in the spleen by 60% as compared to the 40 mg/kg dose. Since the 150 mg/kg was no more effective than 80 mg/kg and caused the death of half the mice within minutes of the injection, a dose of 120 mg/kg was then determined to be the maximal tolerated dose of free drug and, therefore used in subsequent studies.
Dose response of VSI07
The results for both spleen and liver shown indicate the dose response of 120 mg/kg VS107 was better than that of 40 mg/kg (P < 0.001) and that of 320 mg/kg was better than that of 120 mg/kg (P < 0.001) but that the dose response of 240 mg/kg was not statistically different from those of 120 or 320 mg/kg (Figure 2) .
Comparative results of VS107 to free amikacin and controls
In order to more directly compare the effect of VS107 to that of 120 mg/kg free amikacin on infection, doses of 40 mg/kg and 120 mg/kg VS107 were used even though there were no signs of toxicity after 160 mg/kg and only minimal toxicity after 240 mg/kg with the liposomal preparation. Treatment with 120 mg/kg free amikacin treatment resulted in a steady decrease in viable bacteria in the spleen throughout the 51 days of treatment (Figure 1 ) and the viable bacteria in the liver only began to decline after 23 days of treatment whereas treatment with 120 mg/kg VS107 was effective in both the liver and spleen for the entire period. In contrast, treatment with 40 mg/kg VS107 resulted in declining counts in both organs until 37 days and did not further decrease thereafter. Never the less, treatment with 40 mg/kg was significantly more effective than 120 mg/kg free amikacin at each time point throughout treatment (P < 0.001). Treatment with 120 mg/kg VS107 was significantly more effective than with 40 mg/kg from day 23 of treatment onwards (P < 0.001). The effectiveness of treatment with 120 mg/kg VS107 was most dramatic in the liver at 51 days by which time a reduction of 6 logio had been attained when compared with the viable counts of mice treated with buffer or empty liposomes.
Pharmacokinetics
A peak serum concentration of 730 mg/L was obtained and by the third dose of VS107, a brief alpha phase with a half life of approximately 27 min, and beta phase with a half life of 9.1 h were apparent (Figure 3 ).
Discussion
The results obtained in this study confirm reports by others that liposomal delivery of amikacin is very effective in the treatment of experimental MAC infection. Although direct comparisons of specific results are difficult because of differences in the experimental designs and in the composition and concentration of liposomes, our new formulation of liposomal amikacin reduced the viable counts in spleens and livers in the infected mice more effectively, i.e. by 2-3 decimal logarithms, than has been reported previously (Duzgunes et al., 1988; Cynamon et al., 1989 ; Bermudez et al., 1990) . The size of the liposomal vesicles in VS107 are 45-65 nm and are smaller than the 90-110 nm vesicles in the formulation of Bermudez et al. (1990) and the 400 nm vesicles in the drug used by Duzgunes et al. (1988) and treatment with our preparation achieved a reduction in viable bacteria in the liver of six decimal logarithms in mice compared with approximately 3 log, 0 reported by these authors.
When given at the same dose of 120 mg/kg, our liposomal compound was also more active than was the free drug achieving a 5 log reduction in viable bacteria in the spleen and a 6 log reduction in the liver compared with a 3 log reduction obtained with free amikacin. Furthermore, the lower dose of 40 mg/kg liposomal compound was also more active than the highest concentration of 120 mg/kg free amikacin when given for a period of 23 days or longer. These results indicate that iv treatment with VS107 effectively targets the reticuloendothelial system which is involved in widely disseminated MAC infection (Chiu et al., 1990) . The fact that we have demonstrated that the response is related to both the dose and the duration of treatment suggests that this drug may have a wide application in treating clinical infections. Our results show that VS107 was reasonably stable with little drug leakage under simulated physiological condition. We observed an initial loss of approximately 12% of the amikacin from the liposome immediately upon mixing VS107 with rat plasma which was thought to be due to removal of aminoglycoside that was bound to the outer surface of the liposomes. Release of an additional 21% of the encapsulated amikacin over the first hour of incubation with rat plasma may be due to preferential protein association and disruption of a subset of the total liposome population, although no attempt has been made to characterise them. However, the lack of further drug leakage from VS107 is an indication of the unique stability of this formulation and suggests that the long circulation half-life is accounted for by the amikacin which remains within the circulating liposomes, and not by drug which has leached out of the liposomes and become bound to plasma proteins. VS107 produced very high plasma amikacin levels and a long terminal half-life in CD-I mice. Previous studies of non-liposomal amikacin administered subcutaneously to mice at a dose of 40 mg/kg reported peak serum concentrations of approximately 50 mg/L and an elimination half life of only 24 min (Kawaguchi et al., 1972) . Thus, much higher dosages of amikacin can be delivered using a liposomal formulation and elimination of the drug is markedly delayed. However, further studies are needed to determine how much of the high total amikacin levels is due to free drug.
The increased activity of VS107 to that of free amikacin most likely relates to several factors including the prolonged half-life and higher serum concentrations. This liposomal amikacin was also shown to be superior to free amikacin in an in-vitro culture system of mycobacteria growing in human macrophages (L. Heifets & N. Mor, unpublished observations) suggesting that liposome encapsulation can enhance intracellular uptake of amikacin which, together with the stability of the formulation, most likely contributed significantly to the improved containment of infection we observed.
Reduced toxicity is another potential advantage of liposomal encapsulation and has been shown to reduce the nephrotoxicity of other drugs, e.g. amphotericin B (Meunier, Prentice & Ringden, 1991; Proffitt et al., 1991) . Our preliminary toxicity studies have shown minimal histological toxicity to the kidneys in mice given large doses of VS107 (data not shown). However, while encouraging, much more extensive studies are needed to confirm this.
Our formulation of liposome encapsulated amikacin therefore appears a suitable candidate for treating patients with disseminated MAC disease and warrants further investigation.
